Blood-stage Malaria Vaccine Candidate RH5.1/Matrix-M Trial in Tanzania

A recent phase 1b trial has been conducted to evaluate the safety and immunogenicity of the blood-stage malaria vaccine candidate RH5.1/Matrix-M in healthy Tanzanian adults and children. This open-label, non-randomised, first-in-human, single-centre trial represents a crucial advancement in the development of a vaccine against malaria, a disease that continues to pose a significant health burden in many parts of the world, particularly in sub-Saharan Africa. The trial's findings are expected to contribute valuable insights into the potential of RH5.1/Matrix-M as a viable vaccine candidate for malaria prevention.